C-W1OIJocasta Neuroscience
Klotho protein, cognitive health, neurodegeneration
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-W1OI
C-W1OIC-W1OIKlotho protein, cognitive health, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
蛋白质疗法研究商Jocasta Neuroscience获得3500万美元A轮融资，以推进管理认知障碍的长寿蛋白项目-动脉网 APP 扫码下载 产业链接 公众号矩阵 动脉网 动脉新医药 动脉橙果局 产业链接 VBEF发布 动脉生物制造 透皮技术创新联盟TTIA 动脉智库 活动会议 2025数字疗法大会 CSGCT第二届中国细胞与基因治疗大会 2026未来医疗100强大会 2025VBEF直播回放&百强榜单 全部活动 解决方案 动脉AI 搜索 EN 登录 首页 情报 原创 专题 报告 链接 直播 活动 动脉网APP 扫码下载 蛋白质疗法研究商Jocasta Neuroscience获得3500万美元A轮融资，以推进管理认知障碍的长寿蛋白项目 Jocasta Neuroscience Lands $35 Million Series A to Advance Longevity Protein Program for Managing Cognitive Impairment CISION 等信源发布 2025-08-12 22:00 可切换为仅中文 微信扫码分享 Funding to support development of proprietary * a -Klotho *protein therapeutic targe
Jocasta Neurosciences Secures $35M for Cognitive Decline Reversal | Future Techly posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i
Home News Contact News Contact Cognitive vitality. Genetically validated. Jocasta is driven by leading experts in cognitive health, including Dr. Dena Dubal, Dr, Dr. Albert Agro, PhD and Dr. Ned David. meet the people behind jocasta → Powering the potential oF Klotho We are all born with a gene for producing the Klotho protein, though some produce more than others. This protein circulates in the blood, protecting the brain and reducing toxicity. However, chronic stress and aging deplete it. But what if we could replenish it? Around 1 in 4 people carry the KL-VS allele, which boosts circulating
Albert Agro - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Albert Agro Executive Officer at Jocasta Neuroscience, Inc. Albert Agro 's Executive Work History Current Executive Officer , Executive Officer Equilar on 11/12/2024 Jocasta Neuroscience, Inc. Board Member , Board Member Equilar on 11/12/2024 Jocasta Neuroscience, Inc. Past To view Albert Agro's complete executive work histo
A breakthrough in Alzheimer's ... – The Peter Attia Drive – Apple Podcasts Suchen Startseite Neu Top-Charts Suchen 27. Mai 2024 2 Std. 5 Min. A breakthrough in Alzheimer's disease: the promising potential of klotho for brain health, cognitive decline, and as a therapeutic tool for Alzheimer's disease | Dena Dubal, M.D., Ph.D. The Peter Attia Drive Wiedergeben View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Dena Dubal is a physician-scientist and professor of neurology at UCSF whose work focuses on mechanisms of
Sell or Invest in Jocasta Neuroscience Stock Pre-IPO Products Our Products Liquidity Solutions Tender offers and liquidity programs Investment Platform Buy and sell private company stock Data & Intelligence Private market pricing and valuations products Settlement Patented Private share transfer technology Capital Solutions Primary raises and fund structures WealthConnect Equity-specific tax and wealth advice Buy and Sell Pre-IPO Stock Trade private company shares with vetted buyers and sellers on a regulated marketplace. Sign Up Log In Use Cases Use Cases Employees & Shareholders Sel
Series A financing at Jocasta Neuroscience to advance JN-0413 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape
Peptides for Cognitive Enhancement & Dementia Prevention | NeuroAge Blog Have an Alzheimer's or MCI diagnosis? Receive a free test by participating in our study → Resources Products Events Partnering Demo Login Back to Blog Peptides for Cognitive Enhancement & Dementia Prevention A review of popular peptides including GLP1-RAs, SS-31, BPC-157, and Cerebrolysin Dr. Christin Glorioso, MD PhD December 20, 2025 22 min read The global peptide therapeutics market was estimated at a whopping $117B in 2024 and is continuing to grow. The leading edge of that market is driven by popular pep … . Time to progression to dementia was also unaffected. Why This Failure May Not Apply to Prevention 1. The Epidemiological Signal Points to Prevention, Not Treatment Real-world data from over 1 million patients with type 2 diabetes consistently shows that semaglutide users have 40-70% lower risk of first-time Alzheimer’s diagnosis compared to other diabetes medications . This signal suggests influence on early pathogenic processes rather than established neurodegeneration. As … Asia. The reasons for its absence from the US market are multifactorial: No FDA Application Filed: Ever Neuro Pharma, the Austrian manufacturer, has not pursued FDA approval. The FDA does not proactively approve drugs—companies must submit New Drug Applications with Phase 1-3 trial data meeting FDA standards. Without a sponsor willing to invest in US trials, approval cannot occur. Inconsistent Trial Results: While dementia trials show benefit, the CASTA stroke trial failure a
Serum Klotho Levels, Brain Structure, and... : JAMA Neurology Ovid ® Beta Ovid Logo Search Ovid Search Ovid JAMA Neurology Navbar Menu Current Issue Previous Issues Latest Articles More menu items Search Journal Search Journal Button group. Check Access Share Cite Permissions Serum Klotho Levels, Brain Structure, and Cognitive Performance Alec M. Czaplicki 2 Ira Frahmand Driscoll 2 Yue Ma 2 J. Max Gaitán 2 Barbara B. Bendlin 4 Sterling C. Johnson 3 Sanjay Asthana 4 Dena B. Dubal 6 Ozioma C. Okonkwo 3 Authors and Affiliations JAMA Neurology 83 ( 3 ) :p 259 - 268 , March 2026 . | DOI: 10.1001/ja … ining, AI training, and similar technologies. Related Articles Customer Service Submit a Service Request Browse the help center Privacy policy Open Access Policy Legal disclaimer Terms and Copyright Manage Cookie Preferences Your California Privacy Choices Copyright © 2026 Wolters Kluwer N.V. and/or its subsidiaries or third-party licensors. All rights reserved, including those for text and data mining and artificial intelligence training. For all open access content, th … ntelligence training. For all open access content, the relevant licensing terms apply.
UBX Stock Price, News & Analysis | Unity Btech --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas Defense & Mil … le share of Series A Preferred Stock designed solely to vote on the dissolution proposal in proportion to the common stock vote. A definitive proxy statement on Schedule 14A dated August 11, 2025 calls a special meeting of stockholders for September 18, 2025 to vote on approval of the liquidation and dissolution of the company and the Plan of Complete Liquidation and Dissolution. The proxy statement notes that, based on information available at the time, UNITY expected there
UNITY Biotechnology and Jocasta Neuroscience license agreement | WyrickRobbins Skip to Main Content Practices Appellate Litigation Banking & Financial Institutions Capital Markets Commercial Litigation Commercial Real Estate Emerging Companies & Venture Capital Employee Benefits & Executive Compensation Environmental & Regulatory Government Contracting Healthcare Investment Funds Labor & Employment Lending & Commercial Finance Licensing & Technology Transactions Mergers & Acquisitions Privacy & Data Security Tax Trademarks Trusts & Estates Peopl
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.1 License Revenue and Agreements 3 Months Ended Mar. 31, 2022 Research And Development [Abstract]   License Revenue and Agreements 5. License Revenue and Agreements   The Company has entered into license agreements with other pharmaceutical and biotechnology companies. The Company’s accounts receivable balances may contain billed and unbilled amounts from milestones and other contingent payments. The Company performs a regular review of its customers’ credit risk and payment histories, including payments made after period end. Hist … e license of intellectual property and delivery of know-how was recognized upon grant of license and delivery of know-how. The transaction price allocated the transfer of licensed compounds and materials, will be recognized over time as the materials are delivered. Consideration received in advance are recorded as deferred revenue and will be recognized as the performance obligations are satisfied. For the three months ended March 31, 2022 and 2021, the Company did not recogn … s include the advancement of additional compounds into Investigational New Drug application (“IND”) enabling studies, the filing of an IND, the commencement of clinical studies, Food and Drug Administration (“FDA”) and/or European Medicines Agency approval, and a net sales threshold. The Bcl License Agreement also includes tiered royalties in the low-single digits based on sales of licensed products. As of March 31, 2022, pursuant to these agreements,
ubx-8k_20211217.htm false 0001463361 0001463361 2021-12-17 2021-12-17   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021     UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter)     Delaware   001-38470   26-4726035 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Id
%PDF-1.4 1 0 obj > endobj 3 0 obj > endobj 4 0 obj [/Pattern /DeviceRGB] endobj 6 0 obj > stream ����JFIFHH��C ��C ��d�"�� ���}!1AQa"q2���#B��R��$3br� %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������� ���w!1AQaq"2�B���� #3R�br� $4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
%PDF-1.7 %���� 8 0 obj > stream x��\Y��6~�_����>���5]A �h`��\�b�f�@~~(Y����T��'�t� \�lJ�>RI��&��N��S1;�V��R��w?��s�NDC��I(��:m��bg�M"����O�_� %b�#��l�u����������O�7�������:�N��t�=�X.�|w����:v6vQ��t�'_qf~�9"�c�2���r~)?�R1-h�nE���Q�'4��i�@J�U n����������������o����\-�%�����#ɡL�ꈌ� >�Ii���� HV�&�nx���kK��+�vS��OX�mp~j��#��)�05���h� Q���OДI����4� #�8��a�ʠ�S�*�V����F�NF|�� �A.���H4�Ϭn�`���F�EU�03n��v:�T�?^؈� r�/��n��m�/���ۿ�._ZIU�we����o�A�~�QĘ�# w_$g�9{����>D ��&mea�w+b�6��Q�P~:�]Ԏ ��3P�t��r;t��p�P��S ���E%��c�$%> �vՆ���t �q��i��Wk��v�g��A�M�P^�� 6�4-��n�ֈ��d6� … tream endobj 161 0 obj > stream ����JFIF����[�http://ns.adobe.com/xap/1.0/ application/postscript dsp035a File Name: dsp035a.ai
Username: A6882
Local Time: 23-Apr-2025 14:16:35
EST Time: 23-Apr-2025 04:46:35
Script Version: 2.6
Illustrator Version: 29.4.0
Graphic type: Pie Chart

• 6 CMYK black objects changed to grayscale.

• 13 CMYK black characters changed to grayscale.

The following fonts are present in the document:&# … tream endobj 162 0 obj > stream ����JFIF����cxhttp://ns.adobe.com/xap/1.0/ application/postscript dsp035b File Name: dsp035b.ai
Username: A6882
Local Time: 23-Apr-2025 14:16:42
EST Time: 23-Apr-2025 04:46:42
Script Version: 2.6
Illustrator Version: 29.4.0
Graphic type: Pie Chart

• 5 CMYK black objects changed to grayscale.

• 13 CMYK black characters changed to grayscale.

The following fonts are present in the document:&# … uJ/wC1l/3M
cd/L7Fd/uJ/7WX/cxx38vsVTuP0F9Xl+sfpD0ODetz/SPHhT4uVe1MRxeX2J3f/Z application/postscript dsp050 File Name: dsp050.ai
Username: rr615570
Local Time: 23-Apr-2025 14:32:29
EST Time: 23-Apr-2025 05:02:29
Script Version: 2.6
Illustrator Version: 25.0.0
Graphic type: Bar Chart

• 1 hairline rules changed to 0.25.

• 1 black rules changed to overprint.

The following fonts are present in the document:
 Times-Roman
 … tream endobj 248 0 obj > stream ����JFIF����bXhttp://ns.adobe.com/xap/1.0/ application/postscript dsp051 File Name: dsp051.ai
Username: rr615570
Local Time: 23-Apr-2025 15:04:21
EST Time: 23-Apr-2025 05:34:21
Script Version: 2.6
Illustrator Version: 25.0.0
Graphic type: Bar Chart

• 1 hairline rules changed to
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Latest Progress of Biosciences in Arizona - Flinn Foundation You are using an outdated browser and some functions on our site may not function correctly. Here's how you can upgrade your browser easily. Bioscience Flinn Scholars Arts and Culture Civic Leadership Conference Center About Flinn Newsletters Contact Conference Center Using The Center About the Conference Center Book a Room Apply for Booking Access Caterers About Flinn General Information The Flinn Foundation operates in four philanthropic areas Grantmaking Guidelines Active Grants Our history Our values Inclusive Excellence S … ence Bioscience Grantmaking Bioscience Grants Translational Seed Grants Program Apply Program Participants Bioscience Entrepreneurship Program Apply Program Participants Resources Bio Blog What is Bioscience? Bioscience Directory Arizona BioMap Why Arizona? News and Updates Flinn Scholars The Scholarship Apply for the Flinn Scholarship Application Timeline Application Requirements Tips for Applicants Tips for Parents Tips for Recommenders Information Session Scholarship Benef … s SMU DataArts Resources News and Updates Civic Leadership Programs Flinn-Brown Fellowship Flinn-Brown FAQs Apply for Flinn-Brown Flinn-Brown Academy Flinn-Brown Academy Facilitators Flinn-Brown Convention 2026 Flinn-Brown Convention 2025 Flinn-Brown Convention 2024 Flinn-Brown Convention 2023 Flinn-Brown Convention 2022 Flinn-Brown Convention 2021 Flinn-Brown Convention Fellows Directory Meet the 2026 Flinn-Brown Fellows Meet the 2025 Flinn-Brown Fellows Meet the 2024 Flinn- … ases, and several bio startups. Mayo Clinic, ASU partner on degree: A five-year grant from the Flinn Foundation supports a full-time, three-semester program held on ASU and Mayo Clinic campuses. The program, which welcomes its first class, immerses bio engineering students in clinical settings at Mayo, where they receive hands-on experiential learning. Separately, Mayo and ASU researchers partner on numerous research initiatives, including one to develop a rapid Valley fever … es. Accelerate Research into Impact U of A receives joint $43.6 million federal grant: The seven-year NIH grant under the prestigious Clinical and Translational Science Awards Program enables U of A and the University of New Mexico to support translational science to help drive research into clinical practice. The award funds a new Southwest Cent
Share Ventures — VC Fund Profile | Waveup Copilot Assisted fundraising Log in | Sign up Home Guides Assets Investors VC funds Tailored lists Favorites Academy Privacy policy Terms of Use Privacy Policy Help center Return to waveup.com Fund profile Share Ventures Culver City, USA Leading About Share Ventures is a Culver City, California-based venture studio and early-stage investor founded in 2020 by Hamet A. Watt — MoviePass co-founder and former partner at Upfront Ventures. The firm operates at the intersection of human performance and artificial intelligence, combining an in-house ideation a … elligence, combining an in-house ideation and incubation lab with an investment fund. Most portfolio companies are co-founded and incubated internally rather than sourced externally, giving Share Ventures deep operational involvement from day one. Strategic LPs and backers include True Ventures, Upfront Ventures, Alpha Edison, Google, and Amazon, who collectively supported the firm's approximately $10 million core studio vehicle. Share Ventures leads rounds and writes initial … ists Filter by Sort by Contacts Website share.vc Social Lists that include this fund
Jocasta Neuroscience Lands $35 Million Series A to Advance Longevity Protein Program for Managing Cognitive Impairment | Dena Dubal | 22 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cl
News News Contact News Contact News Peripheral Klotho Fragment Improves Brain Resilience in Aging and Parkinson’s Models A 2017 study in Cell Reports shows that peripheral delivery of a klotho protein fragment enhances cognition and neural resilience in young, aging, and α-synuclein transgenic mice, despite not crossing the blood-brain barrier. Read More → MEDIA Check back soon! news & PUBLICATIONS News 8.12.25 Exclusive: Jocasta Neuroscience raises $35M Exclusive: Jocasta Neuroscience raises $35M for clinical development Learn More News 8.12.25 Jocasta Neuroscience Lands $35 Million Serie
%PDF-1.7 %���� 501 0 obj > endobj xref 501 26 0000000016 00000 n 0000001924 00000 n 0000002079 00000 n 0000003545 00000 n 0000004106 00000 n 0000004725 00000 n 0000004762 00000 n 0000004809 00000 n 0000005373 00000 n 0000005487 00000 n 0000005646 00000 n 0000006240 00000 n 0000006625 00000 n 0000007077 00000 n 0000007431 00000 n 0000007849 00000 n 0000010384 00000 n 0000013033 00000 n 0000013415 00000 n 0000013817 00000 n 0000018215 00000 n 0000018325 00000 n 0000679200 00000 n 0000702718 00000 n 0000706745 00000 n 0000000816 00000 n trailer ]/Prev 4187048>> startxref 0 %%EOF 526 0 obj >stream … �k�M���Nj�[����/B#jz��]�Ncp?>v�����&]S��1[Ӄ�.�6S����S���e|Kt6�b�l��7���RFp�\^3����O�!��ͺ 9�.ꨀ��j|L���W����E������ʥ��! x�t�e�(.��^�����/~��'2 B �뤇W�fAx%c�b:{S1��2ҡM)��Ӱ\~�V���>� ��zJ�-�� �6L�@ķ���*��M�x�b\e�����Ա��9��~D��=F+���v����FPh�~�W ���`�VuW��ܔN��� "��4C���T�ô3ՍJXqe�*���{�l@�h=w���:8bDZ*� ~Q�Փ��S i��ōq��{W+YZ܃�9Z�Ld����o4`jIk�%Xc�Z:�ʮ�H%6!�"�v� �$`��=6� -��>��� #H�e q'ɉ�R�ɺ����cU��t���@���k�^xu�i����"� ��nT&o … n,7%��og��� �h��YO�������Y�V��0���Ѧ endstream endobj 52 0 obj >stream application/pdf Asset 1 Adobe Illustrator 29.3 (Macintosh) 2025-03-25T09:42:40-04:00 2025-03-25T09:42:40-04:00 2025-03-25T09:42:40-04:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:f1cee0fc-fdf1-44c6-b699-76b3dca1e609 uuid:2af69207-e82e-ea41-88bc-d45a373b6176 uuid:27f584af-a488-9349-a64a-b29a9af20ed9 xmp.did:8d08eb9c-7571-4e78-aade-d88bdc677e5e uuid:65E6390686CF11DBA6E2D887CEACB407 pro … (�:l� ���{�w��g ��ܾ����]��Vs�`�9�ח� ���� endstream endobj 94 0 obj >stream application/pdf Asset 3 Adobe Illustrator 29.3 (Macintosh) 2025-03-27T16:00:27-04:00 2025-03-27T16:00:27-04:00 2025-03-27T16:00:27-04:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:f1cee0fc-fdf1-44c6-b699-76b3dca1e609 uuid:7f369d11-1bbb-d448-a766-1f4e0ba263a8 uuid:27f584af-a488-9349-a64a-b29a9af20ed9 xmp.did:8d08eb9c-7571-4e78-aade-d88bdc677e5e uuid:65E6390686CF11DBA6E2D887CEACB407 pro … �% endstream endobj 174 0 obj > endobj 175 0 obj > endobj 176 0 obj >stream application/pdf Asset 4 Adobe Illustrator 29.3 (Macintosh) 2025-03-27T16:36:01-04:00 2025-03-27T16:36:01-04:00 2025-03-27T16:36:01-04:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:f1cee0fc-fdf1-44c6-b699-76b3dca1e609 uuid:e19b25df-a6d8-a04c-9a4b-bc1dc68e5
Briana Yesilli - Associate // Cooley // Global Law Firm Skip to main content Contact News Events Alumni Sign up About People Services Insights Diversity Careers Geographies Associate Briana Yesilli [email protected] Full contact info About In depth Related news and events About Briana Briana is an associate in our corporate practice group and her focus centers largely around the representation of privately held emerging and high growth companies, as well as venture capital, private equity funds, family offices and corporate venture groups that invest in those companies. Her work with compani
Fresh leads from today’s business news. NewsletterForLeads.com Search Sign Up Now Open main menu Sign Up Now Fresh leads from today’s business news. We scan the headlines. You cash the commissions. Jun 27, 2026 Ecore COO Appointment: Ops & SCM Pipeline Alert Ecore taps Jeff Coté as President & COO. Ops & Supply Chain vendors: next-touch pipeline is hot. Close deals and boost commission. Read More Jun 27, 2026 Acuren + NV5 Merger: High-Intent TICC Goldmine Spot Acuren’s post-merger tech procurement signals. Fuel your pipeline with high-intent TICC, engineering & geospatial leads … HR & People procurement ahead. Sales reps: engage CHROs now to shape their RFP. Fill your pipeline and close commission-worthy deals. Read More Jun 27, 2026 Deal-Flow Alert: agilon health Q2 ’25 Buying Signals Boost your pipeline. agilon health’s Q2 ’25 results and exec shake-up send deal-flow alerts on AI-ops, data visibility, and cost-cut solutions. Read More Jun 27, 2026 Quota Alert: ZoomInfo CFO Sparks Finance Deal Flow ZoomInfo just tapped Graham O’Brien as permanen … urance to lock in deal flow. Read More Jun 27, 2026 Sales Trigger: The O.H.I.O. Fund Hits $238M One-year, $106M close. $238M AUM. Ray Leach needs real-time fund analytics. Pitch instant dashboards. Expand with AI deal sourcing. Dial for deal flow. Read More Jun 27, 2026 Battle Card: JLL Partners Sales Trigger Maggie Anderson joins JLL Partners as Operating Partner. Pitch real-time ops analytics & supply chain consulting to scale 60+ investments. Connect. Close. Read More … pipeline and commission. Read More Jun 27, 2026 Battle Card: JMI Equity’s $3.1B Fund Close JMI Equity nailed a $3.1B fund close. New pipeline budget unlocked for growth-stage software. Hit Preston Horner, Andy Knox & Will Priestley. Pitch real-time portfolio analytics & automated deal sourcing. Read More Jun 27, 2026 Sales Trigger: Ibotta CFO Hire Ibotta names Matt Puckett as CFO. Pitch FP&A analytics and investor relations CRM. Fuel your pipeline and close deals … it your quota. ✅ Quick checklist inside. Read More Jun 27, 2026 Pipeline Alert: Grant Thornton's 91-Partner Surge Grant Thornton just added 91 partners. Automate HR onboarding to slash ramp time, unify new leaders, and stack up deals. Next touch: now. Read More Jun 27, 2026 House of Bricks Sales Trigger: Advisory Alert Tim Cripsey joins Hous
Moore Capital Management | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors Moore Capital Management Moore Capital Management New York City, New York moorecap.com Overview Moore Capital Management is a private investment management firm that invests in the global financial markets and private equity markets, primarily utilizing a global macro strategy. Year Founded 1989 AUM $27.98B Portfolio Companies 37 Website moorecap.com Investments Company Date Stage Lead XFlow Feb
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
📺 Axios Pro Rata: Broadcast news | NewsletterHunt NewsletterHunt Logo NewsletterHunt Logo NewsletterHunt Open main menu Latest Sign Up Sign In Latest Sign In Sign Up Pro Rata 📺 Axios Pro Rata: Broadcast news 11 months ago bookmarks#create" data-bookmarks-target="bookmark" type="button" class="inline-flex items-center rounded-md border border-brand bg-white px-3 py-2 text-sm font-bold leading-4 text-brand shadow-sm hover:bg-brand-100 focus:outline-none focus:ring-2 focus:ring-brand focus:ring-offset-2"> iframe#adjustHeight resize@window->iframe#adjustHeight" seamless scrolling="no" frameborde … ;"> <p><strong>The U.S. doesn't have a sovereign wealth fund,</strong> at least not yet, but there are several sovereign wealth funds within the country.</p> <ul> <li>These are funds established by Native American tribes, totaling billions of dollars.</li> <li>The third-largest is for the Chickasaw Nation, an Oklahoma-based tribe that claims more than 80,000 citizens. It also may be the only one with a wholly owned p … le maintaining the same internal return profile as a traditional private equity fund paying less.</li></ul> </td> </tr> <tr> <td align="center" style="padding:20px 3.5% 25px 3.5%;"> <img width="32" height="32" style="border:: 100% !important;max-width:100% !important;" target="_blank" src="https://static.axios.com/img/axios-site/newsletters/logos/footer/share-facebook-circl … General Catalyst</strong> led, joined by Depth VC, Elsa Ventures, Weekend Fund, Flex Capital, Allison Pickens, and 20Sales. axios.link/4mbHZMX</p> <p>🌎 <strong>Green Steel Environmental</strong>, a Boulder, Colo.-based developer of wastewater and biogas treatment tech, raised $1.7m. <strong>The Central Texas Angel Network</strong> led, joined by Cowtown Angels. axios.link/4mbGsXd</p> <p>• <strong>Laurel</strong&g … ong>H.I.G. Capital</strong> raised $5.9b for its fourth direct lending fund. whitehorse.com</p> <p>• <strong>JMI Equity</strong> raised $3.1b for its 12th software-focused growth equity fund. It also promoted Preston Horner and Andy Knox to principals, and Will Priestley to VP. axios.link/3UnOEaI</p> <p&g
10-K http://fasb.org/us-gaap/2022#DomesticPlanMember 0.1 http://fasb.org/us-gaap/2022#LicenseMember 0.1 http://fasb.org/us-gaap/2022#LicenseMember http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent 3 0001463361 http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent 1 FY false 1 0001463361 ubx:EarlyExercisedCommonStockSubjectToFutureVestingMember 2020-01-01 2020-12-31 0001463361 ubx:JocastaNeuroscienceIncMember ubx:LicenseAgreementMember 2022-01-01 2022-12-31 0001463361 ubx:SouthSanFranciscoCaliforniaMember ubx:OfficeAndLaboratorySpaceSecondFloorMember 2022-05-01 2022-05-31 0001463361 2019- … eding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth comp … ls in healthy tissue.   In July 2020, we filed an Investigational New Drug application, or IND, to commence a Phase 1, first-in-human, open-label, single-ascending dose study of UBX1325 in patients with advanced diabetic macular edema, or DME, and neovascular age-related macular degeneration, or nAMD. Our goal with UBX1325 is to transformationally improve outcomes for patients with DME, nAMD, and diabetic retinopathy, or DR. In October 2020, the Phase 1, first-in-human, … 325 in patients with DME evaluated though 24 weeks. Patients have the option of rolling over to a 48-week long term extension and a majority of patients who have completed their 24-week visits have opted to remain in the study. A total of 65 patients were enrolled, randomized evenly between UBX1325 and sham-injected patients. These patients were being actively treated with anti-VEGF for at least 6 months prior to being randomized into the BEHOLD study (mean of 4.03 injections … and Development Plan   In July 2020, we filed an Investigational New Drug application, or IND, to commence a Phase 1, first-in-human, open-label, single-ascending dose study of UBX1325 in patients with advanced diabetic macular edema, or DME, and neovascular age-related macular degeneration, or nAMD. Our goal with UBX1325 is to transformati
Forbes’ 25 Next Unicorns🦄, Women Now Hold 20% of Top VC Roles👩💼, The Case for Optimism🌟 The VC Corner Subscribe Sign in Forbes’ 25 Next Unicorns🦄, Women Now Hold 20% of Top VC Roles👩💼, The Case for Optimism🌟 Ruben Dominguez Aug 17, 2025 57 1 3 Share Another week, another pulse check on venture. From top insights and reports to new funds, VC jobs, resources, and the hottest deals, here’s everything you need to stay ahead. Let’s dive in 👇 Brought to you by Harmonic - the complete startup database Prepare your deal review meetings in minutes. With the new deal search , you can: Automat … r-thin margins investors are eyeing. [ Tom Dotan ] Are Secondaries Coming to VC Fund Rules? 📜 Two proposed U.S. laws could expand what venture funds can invest in, adding secondaries and fund-of-funds to the mix. They would also raise investor caps for 3(c)(1) funds. [TheFundLawyer] Why Most VC Firms Hire Associates Wrong 🔍 Mike Dauber says firms treat associates as disposable leverage instead of future partners. Amplify’s approach invests in mentorship and long-term career … um. The data points to a market reshuffling rather than a full recovery. Global Fund Performance Report – Q4 2024 & Preliminary Q1 2025 Data 📊 PitchBook’s latest report finds private capital’s tentative rebound slipping in early 2025. U.S. tariffs, inflation, and weaker exits are shaping global fund performance. State of VC 2025 - New Capital Dynamics 📊 Carta’s data shows longer gaps between rounds, record-high seed valuations, and smaller teams. Investors are pushing l … ently Launched Funds 💸 GoalVest closed the first tranche of its Venture Growth Fund II, aiming for a $50M target. Hatteras Venture Partners raised over $200M across two healthcare-focused venture funds to support innovation in biotech and life sciences. Scenius Capital launched a $20M fund-of-funds to invest in emerging managers and early-stage funds. L JMI Equity closed a $3.1B fund focused on software investments, marking one of its largest vehicles to date. Immortal Drago … , marking one of its largest vehicles to date. Immortal Dragons d ebuted a $40M fund targeting longevity and biotech startups pushing the boundaries of human healthspan. Frachtis introduced its first-ever pre-seed crypto fund, supporting founders building foundational web3 infrastructure. Acquisition.com rolled out ACQ Ventures to back scalable,
Moore Strategic Ventures - Investor Profile, Portfolio, Investments & Team ☰ Fund List --> View Investors --> Submit Investor Profile --> Claim Account --> --> Investor List --> View Investors --> Submit Investor Profile --> Claim Account --> --> Startup List --> View Startups --> Submit Startup Profile --> Claim Account --> --> Deals Pricing --> --> Events --> --> --> 注册 --> Login --> Login Home Fund Moore Strategic Ventures --> Year Founded: --> --> --> Moore Strategic Ventures https://www.moorecap.com Claim Profile Submit Deck Become LP Location: New York, NY USA Investor Type: Pr
tenx_10k.htm 0000034956 false --12-31 Non-accelerated Filer FY 2023 false 0.0001 400000000 28648 4818654 0.0001 5181346 210 0 0 1722240 1722240 15.87 0 970 1000000.0 0.21 0000034956 2023-01-01 2023-12-31 0000034956 us-gaap:SubsequentEventMember tenx:RothCapitalPartnersLlcMember 2024-02-01 2024-02-08 0000034956 us-gaap:SubsequentEventMember 2024-02-01 2024-02-19 0000034956 us-gaap:SubsequentEventMember 2024-01-01 2024-01-18 0000034956 us-gaap:SubsequentEventMember 2024-02-01 2024-02-22 0000034956 us-gaap:SubsequentEventMember 2024-01-11 0000034956 us-gaap:SubsequentEventMember tenx:RothCapitalP … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth compan … oking statements:   ·   our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; · our ongoing evaluation of strategic alternatives; · our ability to develop our current product candidates, and any product candidate which we may develop or in-license in the future; · our ability, our partners’ abilities, and third parties’ abilities to protect and assert intellectual propert … egic process announced in September 2022, and having raised capital expected to fund the Company through 2024, the Company has elected to prioritize its LEVEL trial (Phase 3 testing of oral levosimendan), ahead of imatinib. Activity to initiate the LEVEL trial continued in the fourth quarter of 2023, and site qualification, selection, and initiation processes are ongoing, the Company having received U.S. Food and Drug Administration (“FDA”) input into the oral lev … r subsequent development, product approval, and commercialization. We intend to submit marketing authorization applications following two Phase 3 trials of levosimendan and, when appropriate, a single Phase 3 trial of imatinib. Our trials are designed to incorporate and reflect advanced clinical trial design science and the regulatory and advisor
Jocasta Neuroscience raises $35M for dementia treatment | BYTE51data posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree … Frazier Life Sciences , Andera Partners , Deep Track Capital, Bayern Kapital , Fund+, OCCIDENT, Seventure Partners , and HTGF | High-Tech Gründerfonds . 👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮! News Link ➡️ https://lnkd.in/dVnzqX-A Dominik Schumacher Jonas Helma-Smets Ingo Lehrke Günter Fingerle-Rowson Bjoern Hock Matthew Norkunas, M.D. Halley Gilbert Armin Weidmann Sofiya Lyn Philipp Sakuler 8 Like Comment Share Copy LinkedIn Facebook X To view o … hlin and Lorence Kim have been able to collect $325 million for their inaugural fund at their Florida firm Ascenta Capital. They had targeted $350 million but decided to close the first fund early in the summer because their six-company portfolio was gaining momentum. “It’s a tough environment to raise a new fund focused on biotech that doesn’t have the letters ‘A’ and ‘I’ in it, but we did do an AI deal, actually, in biotech [Iambic Therapeutics] that’s going great,” Rachlin … Capital , based in West Palm Beach, has successfully closed its inaugural $325M fund focused on development-stage biotechnology companies. The firm was founded in 2023 by Dr. Evan Rachlin and Dr. Lorence Kim , both former Moderna executives who bring deep operating and investment expertise. What makes this particularly noteworthy: Ascenta's team has contributed to 30+ approved medicines throughout their careers, and they've already deployed over $100M across six portfolio com … at are collectively running 14 clinical trials with 40+ pipeline programs. This fund close reinforces South Florida's emergence as a legitimate medtech hub. The region attracted $572.5M in medtech funding across 45 deals in 2024, with companies like Insightec, DermaSensor, and others leading the charge. The combination of institutional capital, e
https://www.wyrick.com/news-insights/triangle-business-journal-names-wyrick-robbins-a-best-place-to-work-2 https://www.wyrick.com/careers/professional-staff-opportunities/office-services-assistant-3 https://www.wyrick.com/deals/opex-technologies-entered-into-a-strategic-partnership-with-intellys-corporation https://www.wyrick.com/deals/citius-oncology-inc-secured-loan-transaction-and-concurrent-equity-financing-with-avenue-venture-opportunities-fund-ii-l-p-a-fund-of-avenue-capital-group https://www.wyrick.com/news-insights/chambers-partners-recognizes-wyrick-robbins-with-12-rankings-across-fiv … i-and-the-legal-profession https://www.wyrick.com/news-insights/february-2-2026-deadline-for-notices-to-employees-who-purchased-stock-in-2025-through-stock-options-or-employee-stock-purchase-plans https://www.wyrick.com/speeches-pubs/deeply-dehumanizing-degrading-and-violating-deepfake-pornography-and-the-path-to-legal-recourse-72-syracuse-l-rev-335-2023 https://www.wyrick.com/people/emily-m-pascale https://www.wyrick.com/deals/flyexclusive-inc-completes-public-offering-of-co … -insights/wyrick-robbins-recognized-by-lcld-as-a-2025-top-performer-and-compass-award-winner https://www.wyrick.com/speeches-pubs/navigating-scope-requirements-and-risk-in-health-privacy-law-developments-and-trends-north-carolina-bar-association-october-24-2025 https://www.wyrick.com/news-insights/dollar-limitations-for-employee-benefit-plans-2026-update https://www.wyrick.com/news-insights/new-ccpa-risk-assessment-and-automated-decision-making-technology-regulations-maybe-no … www.wyrick.com/news-insights/wyrick-robbins-recognized-with-employee-engagement-award-from-the-2025-health-value-awards https://www.wyrick.com/deals/citius-pharmaceuticals-inc-completes-registered-direct-offering-of-common-stock https://www.wyrick.com/news-insights/todd-eveson-named-law-honoree-in-business-north-carolinas-2025-power-list https://www.wyrick.com/news-insights/the-justice-departments-new-rule-on-access-to-u-s-sensitive-personal-data-and-government-related-data-b … ca-reporting-now-in-effect https://www.wyrick.com/news-insights/january-31-2025-deadline-for-notices-to-employees-who-purchased-stock-in-2024-through-stock-options-or-employee-stock-purchase-plans https://www.wyrick.com/news-insights/three-wyrick-attorneys-selected-for-leadership-council-on-legal-diversity-2025-programs https://www.wyrick.com/new
%PDF-1.4 %���� 418 0 obj > endobj xref 418 25 0000000016 00000 n 0000001461 00000 n 0000001638 00000 n 0000007742 00000 n 0000008302 00000 n 0000008765 00000 n 0000008879 00000 n 0000008970 00000 n 0000009510 00000 n 0000010151 00000 n 0000010494 00000 n 0000010925 00000 n 0000012286 00000 n 0000013543 00000 n 0000014679 00000 n 0000015791 00000 n 0000016917 00000 n 0000017917 00000 n 0000019093 00000 n 0000020067 00000 n 0000025126 00000 n 0000027223 00000 n 0000037014 00000 n 0000001277 00000 n 0000000796 00000 n trailer ]/Prev 490525/XRefStm 1277>> startxref 0 %%EOF 442 0 obj >stream h�b``` … 6f585f83cd xmp.id:63fbe558-8039-4ebd-8b7e-c60efa34dac4 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign 21.3 (Macintosh) / 2026-04-06T17:11:39-07:00 xmp.iid:32858062-ab38-41cc-92cd-6e83909691fa xmp.did:5952b07f-b6ff-44d6-b051-d26f585f83cd xmp.did:5952b07f-b6ff-44d6-b051-d26f585f83cd default application/pdf Adobe PDF Library 18.0 False 1845502165 Whitney OpenType - PS 1845502165 -- 0 Whitney-Book 2.30 1608091019 Whitney OpenType - PS 1608091019
About Us – Tenax Skip to content ☰ ABOUT US LEADERSHIP TEAM BOARD OF DIRECTORS SCIENTIFIC ADVISORY BOARD CLINICAL TRIALS PUBLICATIONS PH-HFpEF SPLANCHNIC CIRCULATION TNX-103 INVESTORS CONTACT US JOIN US × ABOUT US LEADERSHIP TEAM BOARD OF DIRECTORS SCIENTIFIC ADVISORY BOARD CLINICAL TRIALS PUBLICATIONS PH-HFpEF SPLANCHNIC CIRCULATION TNX-103 INVESTORS CONTACT US JOIN US Drug development veterans joined by preeminent cardiology and pulmonary hypertension experts Our management team has decades of experience developing and commercializing many successful cardiovascular products … is MD from Loyola University Stritch School of Medicine, while he completed his residency in medicine at the Washington University in St. Louis and fellowship in cardiology at the University of Chicago. Doug Randall Chief Business Officer Douglas Randall has over 30 years of experience as a pharmaceutical executive across the healthcare industry. He joined Tenax as an Executive Vice President of Business Development and Operations in... READ MORE Doug Randall Chief Business O … is MD from Loyola University Stritch School of Medicine, while he completed his residency in medicine at the Washington University in St. Louis and fellowship in cardiology at the University of Chicago. Scientific Advisory Board Sanjiv Shah, MD CHAIRMAN Dr. Sanjiv Shah is the Stone Endowed Professor of Medicine, Director of Research for the Bluhm Cardiovascular Institute, and Director of the HFpEF Program at Northwestern University Feinberg School of... READ MORE Sanjiv Shah, … active NIH R01 grants and an AHA Strategically Focused Research Network project grant. Dr. Shah has published over 320 peer-reviewed research publications, and he is an Associate Editor for JAMA Cardiology. Barry Borlaug, MD Dr. Borlaug is Professor of Medicine and Director, Circulatory Failure Research, Division of Cardiovascular Diseases, and Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine at the Mayo... READ MORE Barry Borlaug, MD … y and Medical degrees from The Johns Hopkins School of Medicine and completed a fellowship in Cardiology at The Johns Hopkins Hospital. Dr. Burkhoff then... READ MORE Daniel Burkhoff, MD, PHD Dr. Burkhoff obtained Doctor of Philosophy and Medical degrees from The Johns Hopkins School of Medicine and completed a fellowship in Cardiology at The Joh
Jocasta Neuroscience raises $35M for longevity protein program | Pulse 2.0 posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … The round was led by the American Heart Association ’s Go Red for Women Venture Fund, with participation from Norwest , Koch Disruptive Technologies , Esplanade Ventures , Pear VC , Correlation Ventures , and E12 Ventures . The new capital will support operational expansion and continued platform development, strengthening Neura Health’s mission to make specialized neurological care more accessible nationwide. Neura Health was founded by Elizabeth Burstein (CEO) and Sameer Ma … more than optimism, it demands pragmatic execution. With the launch of LongeVC Fund II, we’re doubling down on what we know works: scientific diligence, translational focus, and founders who turn deep tech into tangible outcomes. The fund builds on the track record of Fund I: zero write-offs, a portfolio of companies advancing from concept to clinic, and a thesis that scientific diligence is the strongest form of risk management. Our first investment from Fund II, Trogenix ’ … ticipation 4BIO Capital , Cancer Research Horizons , the Brain Tumor Investment Fund, Eli Lilly and Company , Meltwind Advisory LLP , and Calculus Capital . Fund II continues our commitment to deep scientific diligence, early translational validation, and building long-term value in a sector where timelines are measured in breakthroughs, not quarters. Congratulations to Ken Macnamara and the entire Trogenix team! Read more in the EU-Startups article by David Cendón Garcia : h
Caitlin Courtney - Partner - Related news and events // Cooley // Global Law Firm Skip to main content Contact News Events Alumni Sign up About People Services Insights Diversity Careers Geographies Partner Caitlin Courtney [email protected] Full contact info About In depth Experience Related news and events Filters Sort by Get In Touch Contact [email protected] +1 650 843 5714 Download vCard Location Palo Alto Want to receive alerts from Cooley? Sign up Home People Services Insights About Diversity Careers Geographies Contact us Media RSS Feed Legal Notices & Privacy Policy Attorney
10-K/A FY true 0001463361 0001463361 2024-01-01 2024-12-31 0001463361 2024-06-30 0001463361 2025-03-06 xbrli:shares iso4217:USD   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K/A     (Amendment No. 1)   (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38470   Unity Biotec … eding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth companyR … orm 10-K, which was filed with the SEC on March 7, 2025 as Exhibit 19.1. Equity Award Timing Policies and Practices We generally grant equity awards at regularly scheduled Board of Director or Compensation Committee meetings. We do not grant equity awards in anticipation of the release of material nonpublic information and we do not time the release of material nonpublic information for the purpose of affecting the value of executive compensation. In the event material nonpub … n to the Board of Directors or Compensation Committee before granting an equity award, the Board of Directors or Compensation Committee will consider such information and use its business judgment to determine whether to delay the grant of equity to avoid any appearance of impropriety. During fiscal year 2024, we did not grant stock options or similar option-like instruments to our NEOs during the four business days prior to or the one business day following the filing of our … ;               (1) Amounts reflect the full grant date fair value of stock and option awards granted during 2024 and the incremental fair value of stock options repriced during 2023, in each case, computed in accordance with ASC Topic 718. See Note 14 of the audited financial statements included in our Annual R
PhotoPharmics Announces Board Expansion to Support the Next Phases of Growth: Clinical Execution, Commercialization, and Strategic Partnerships - PhotoPharmics Clinical Pathway Science Leadership Newsroom Investors PhotoPharmics Announces Board Expansion to Support the Next Phases of Growth: Clinical Execution, Commercialization, and Strategic Partnerships Dec 4, 2025 PhotoPharmics, a clinical-stage medical device company developing photo-neuromodulation therapies for neurodegenerative diseases today announced the addition of two widely respected industry leaders to its Board of Directors: W.
JVC Investment Partners | Portfolio of Entrepreneurs, Innovators & Businesses Our Team Portfolio News Legacy Contact Our Team Portfolio News Legacy Contact Portfolio Investing our own capital in people with great vision, technologies and promise ANDE Ande is the global leader in Rapid DNA with a mission to use Rapid DNA to create a safer world. ARCELLX Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. Allogeneic + Switchable Addressing the shortcomings of curren
Jocasta Neuroscience Lands $35 Million Series A to Advance Longevity Protein Program for Managing Cognitive Impairment Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Home News Contact News Contact Cognitive vitality. Genetically validated. Jocasta is driven by leading experts in cognitive health, including Dr. Dena Dubal, Dr, Dr. Albert Agro, PhD and Dr. Ned David. meet the people behind jocasta → Powering the potential oF Klotho We are all born with a gene for producing the Klotho protein, though some produce more than others. This protein circulates in the blood, protecting the brain and reducing toxicity. However, chronic stress and aging deplete it. But what if we could replenish it? Around 1 in 4 people carry the KL-VS allele, which boosts circulating
Healthcare Private Placement and M&A Transactions Review Week Ending November 17, 2024 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending N
Jocasta Neuroscience, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 19 Feb 2026 Jocasta Neuroscience, Inc. Holding Company | 2021 | Illinois, United States | 10-50 | www.jocastaneuro.com Holding Company | 2021 | Illinois, United States | 10-50 | www.jocastaneuro.com Last update 19 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Protein drugs Disease domain score A glimpse into the focused therapeutic areas No Data Technology … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Jocasta Neuroscience Lands $35 Million Series A to Advance Longevity Protein Program for Managing Cognitive Impairment - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business J … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Jocasta Neuroscience Lands $35 Million Series A to Advance Longevity Protein Program for Managing Cognitive Impairment August 13, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Funding to support development of proprietary * a -Klotho *protein therapeutic targeting cognitive decline in neurodegen … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Pulse 2.0 - Jocasta Neuroscience: $35 Million Series A... Facebook Log In Pulse 2.0's Post Pulse 2.0 August 13, 2025 · Shared with Public Jocasta Neuroscience: $35 Million Series A Raised For Advancing Longevity Protein Program: Jocasta Neuroscience is a company focused on improving longevity. Its main product is a special formulation of the protein alpha-Klotho, which may help treat cognitive issues linked to neurodegenerative diseases. The company recently raised $35 million in a Series A financing round. True Ventures, an early-stage venture capital firm, led the funding, with contribu
Jocasta Neuroscience raises $35M for a-Klotho protein to fight neurodegenerative diseases | Life Sciences VCLink posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clic … ristian and his team, with support from visionary investors at Novartis Venture Fund and OrbiMed realized that this wasn’t just about #fibrosis . The same approach could unlock treatments for #oncology , monogenic blood disorders, and even autoimmune diseases. The insight? 👉 Transition from a product to a platform. 👉 Build something that could serve multiple therapeutic frontiers, not just one. But with big opportunities come big debates. Investors pushed for oncology the f … million financing led by its new ownership and investors Thiel Bio and Founders Fund. The funds will aid in expanding the Edison® Histotripsy System into new markets, accelerating clinical indications, and enhancing operational capacity for growth. HistoSonics Announces Oversubscribed $250 Million Growth Financing businesswire.com 1 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Vestbee 14,601 followers 8mo Report this post 🧪Dublin-based biotec … nnecticut Department of Economic and Community Development ’s New Haven cluster award announcement, this is an exciting moment for the city’s growing life sciences ecosystem — and a testament to the groundbreaking innovation happening right here in Connecticut. Learn more from Hartford Business Journal below: 👉 Bexorg: https://lnkd.in/ecsAzbiE 👉 Veradermics: https://lnkd.in/eV84JjiY #ConnecticutInnovation #LifeSciences #BioCT #BiotechNews #NeurodegenerativeResearch #Funding
Jocasta Neuroscience, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 19 Feb 2026 Jocasta Neuroscience, Inc. Holding Company | 2021 | Illinois, United States | 10-50 | www.jocastaneuro.com Holding Company | 2021 | Illinois, United States | 10-50 | www.jocastaneuro.com Last update 19 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Protein drugs Disease domain score A glimpse into the focused therapeutic areas No Data Technology … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Jocasta Neuroscience Secures $35 Million Series A // Cooley // Global Law Firm Skip to main content Contact News Events Alumni Sign up About People Services Insights Diversity Careers Geographies Press Release Jocasta Neuroscience Secures $35 Million Series A August 12, 2025 Share Share on LinkedIn Share on X Share on Facebook Share with Email Chicago – August 12, 2025 – Cooley advised Jocasta Neuroscience, a preclinical-stage, longevity-focused company, on its $35 million Series A financing . Its lead asset, a proprietary formulation of the longevity protein a - Klotho, is used to